Tirzepatide is a dual GIP/GLP-1 receptor agonist and one of the most studied incretin-based research peptides in the current literature. This profile covers its mechanism, receptor pharmacology, and how it fits into metabolic research.
What is Tirzepatide?
Tirzepatide (LY3298176) is a synthetic single-molecule peptide engineered to activate two receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It was developed as a next-generation incretin compound, building on the established pharmacology of GLP-1-only agonists by adding GIP receptor activity.
Dual receptor mechanism
The addition of GIP receptor agonism to GLP-1 activity is the defining feature of Tirzepatide's pharmacology. GIP and GLP-1 are both incretin hormones, but they act through distinct receptor pathways. In research models, simultaneous activation of both pathways has been studied for additive and potentially synergistic effects on insulin signalling, glucose handling and lipid metabolism. The GIP component is also studied for its effects on adipose tissue and energy storage pathways.
How Tirzepatide differs from GLP-1-only compounds
GLP-1 receptor agonists like semaglutide act through a single receptor pathway. Tirzepatide's dual mechanism provides a broader pharmacological profile for research, allowing comparison of single- versus dual-receptor activity in the same experimental system. For researchers building on GLP-1 pharmacology, Tirzepatide represents the next step in the incretin agonist series — and Retatrutide extends it further with triple-receptor activity.
Research findings
Tirzepatide has been extensively studied in clinical trials and preclinical models. The clinical literature documents its effects on body weight, glucose regulation and cardiovascular markers. For researchers, the key interest is in its receptor pharmacology and how the GIP component modifies the GLP-1 baseline. See our comparison article Retatrutide vs Tirzepatide for research for a detailed side-by-side analysis.
Purity and characterisation
Tirzepatide is a larger peptide molecule than many research compounds, making purity characterisation particularly important. Impurities in larger peptides can be structurally similar to the target compound and are best resolved by high-resolution HPLC. Every Tirzepatide batch Pepreta supplies is tested by RP-HPLC to ≥99% purity, with ESI mass spectrometry identity confirmation and LAL endotoxin screening. The Certificate of Analysis is published per batch.
Sourcing Tirzepatide for research
Pepreta supplies Tirzepatide as HPLC-verified lyophilised powder across multiple vial sizes, dispatched from Sydney and Melbourne. For reconstitution guidance see our reconstitution guide. Supplied for laboratory and research use only — not for human or animal consumption.